364 related articles for article (PubMed ID: 27286189)
21. Heterogeneous dimer peptide-conjugated polylysine dendrimer-Fe
Shen JM; Li XX; Fan LL; Zhou X; Han JM; Jia MK; Wu LF; Zhang XX; Chen J
Int J Nanomedicine; 2017; 12():1183-1200. PubMed ID: 28243083
[TBL] [Abstract][Full Text] [Related]
22. ROS-sensitive thioketal-linked polyphosphoester-doxorubicin conjugate for precise phototriggered locoregional chemotherapy.
Pei P; Sun C; Tao W; Li J; Yang X; Wang J
Biomaterials; 2019 Jan; 188():74-82. PubMed ID: 30336287
[TBL] [Abstract][Full Text] [Related]
23. Quantification of DOX bioavailability in biological samples of mice by sensitive and precise HPLC assay.
Zhang C; Wu Y; Dong Y; Xu H; Zhao L
Pharm Biol; 2016; 54(1):55-61. PubMed ID: 25880143
[TBL] [Abstract][Full Text] [Related]
24. Dual-Sensitive Charge-Conversional Polymeric Prodrug for Efficient Codelivery of Demethylcantharidin and Doxorubicin.
Wu Y; Zhou D; Zhang Q; Xie Z; Chen X; Jing X; Huang Y
Biomacromolecules; 2016 Aug; 17(8):2650-61. PubMed ID: 27384255
[TBL] [Abstract][Full Text] [Related]
25. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
[TBL] [Abstract][Full Text] [Related]
26. Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy.
Fonseca MJ; Storm G; Hennink WE; Gerritsen WR; Haisma HJ
J Gene Med; 1999; 1(6):407-14. PubMed ID: 10753066
[TBL] [Abstract][Full Text] [Related]
27. Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy.
Anbharasi V; Cao N; Feng SS
J Biomed Mater Res A; 2010 Sep; 94(3):730-43. PubMed ID: 20225211
[TBL] [Abstract][Full Text] [Related]
28. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.
Yang S; Shim MK; Kim WJ; Choi J; Nam GH; Kim J; Kim J; Moon Y; Kim HY; Park J; Park Y; Kim IS; Ryu JH; Kim K
Biomaterials; 2021 May; 272():120791. PubMed ID: 33831739
[TBL] [Abstract][Full Text] [Related]
29. Lipid nanoemulsions loaded with doxorubicin-oleic acid ionic complex: characterization, in vitro and in vivo studies.
Zhang X; Sun X; Li J; Zhang X; Gong T; Zhang Z
Pharmazie; 2011 Jul; 66(7):496-505. PubMed ID: 21812324
[TBL] [Abstract][Full Text] [Related]
30. Matrix metalloproteinase-sensitive size-shrinkable nanoparticles for deep tumor penetration and pH triggered doxorubicin release.
Ruan S; Cao X; Cun X; Hu G; Zhou Y; Zhang Y; Lu L; He Q; Gao H
Biomaterials; 2015 Aug; 60():100-10. PubMed ID: 25988725
[TBL] [Abstract][Full Text] [Related]
31. Doxorubicin delivery to 3D multicellular spheroids and tumors based on boronic acid-rich chitosan nanoparticles.
Wang X; Zhen X; Wang J; Zhang J; Wu W; Jiang X
Biomaterials; 2013 Jun; 34(19):4667-79. PubMed ID: 23537667
[TBL] [Abstract][Full Text] [Related]
32. Enhanced chemotherapeutic efficacy of the low-dose doxorubicin in breast cancer via nanoparticle delivery system crosslinked hyaluronic acid.
Wang Q; Zhong Y; Liu W; Wang Z; Gu L; Li X; Zheng J; Du H; Zhong Z; Xie F
Drug Deliv; 2019 Dec; 26(1):12-22. PubMed ID: 30691317
[TBL] [Abstract][Full Text] [Related]
33. Doxorubicin-induced co-assembling nanomedicines with temperature-sensitive acidic polymer and their in-situ-forming hydrogels for intratumoral administration.
Wan J; Geng S; Zhao H; Peng X; Zhou Q; Li H; He M; Zhao Y; Yang X; Xu H
J Control Release; 2016 Aug; 235():328-336. PubMed ID: 27282415
[TBL] [Abstract][Full Text] [Related]
34. Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy.
Guo H; Lai Q; Wang W; Wu Y; Zhang C; Liu Y; Yuan Z
Int J Pharm; 2013 Jul; 451(1-2):1-11. PubMed ID: 23618965
[TBL] [Abstract][Full Text] [Related]
35. Synthesis of polydopamine as a new and biocompatible coating of magnetic nanoparticles for delivery of doxorubicin in mouse breast adenocarcinoma.
Zavareh S; Mahdi M; Erfanian S; Hashemi-Moghaddam H
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1073-1084. PubMed ID: 27752764
[TBL] [Abstract][Full Text] [Related]
36. Bile acid-conjugated chondroitin sulfate A-based nanoparticles for tumor-targeted anticancer drug delivery.
Lee JY; Chung SJ; Cho HJ; Kim DD
Eur J Pharm Biopharm; 2015 Aug; 94():532-41. PubMed ID: 26149228
[TBL] [Abstract][Full Text] [Related]
37. Transarterial Infusion of iRGD-Modified ZrO
Xie Y; Qi X; Xu K; Meng X; Chen X; Wang F; Zhong H
J Vasc Interv Radiol; 2019 Dec; 30(12):2026-2035.e2. PubMed ID: 31590966
[TBL] [Abstract][Full Text] [Related]
38. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
[TBL] [Abstract][Full Text] [Related]
39. A novel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicity.
Yuan A; Wu J; Song C; Tang X; Qiao Q; Zhao L; Gong G; Hu Y
J Pharm Sci; 2013 May; 102(5):1626-35. PubMed ID: 23423631
[TBL] [Abstract][Full Text] [Related]
40. Dual subcellular compartment delivery of doxorubicin to overcome drug resistant and enhance antitumor activity.
Song YF; Liu DZ; Cheng Y; Liu M; Ye WL; Zhang BL; Liu XY; Zhou SY
Sci Rep; 2015 Nov; 5():16125. PubMed ID: 26530454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
